Cevidoplenib is under clinical development by Genosco and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to GlobalData, Phase II drugs for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cevidoplenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cevidoplenib overview
Cevidoplenib (SKIO-703) is under development for the treatment of idiopathic thrombocytopenic purpura, systemic lupus erythematosus, acquired (autoimmune) hemolytic anemia, psoriasis, anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis). It is a mesylate salt of SKI-O-592. It is administered through oral route. The drug candidate is a pyrido [4,3,-d] pyrimidin-5-one derivative which targets spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in various cell types. It was also under development for the treatment of rheumatoid arthritis.
Genosco overview
Genosco. (Genosco), a subsidiary of Oscotec Inc, is a clinical-stage biotech company that specializes in the discovery and development of novel kinase inhibitors. The company’s main activities revolve around the use of its proprietary G-SMART platform, which enables the identification of rare sequences and the rapid generation of highly selective compounds. Genosco’s product pipeline includes multiple independent and partnered pipelines, which focus on kinase-targeted therapies. The company’s products are primarily designed for patients with unmet medical needs, particularly in the field of precision medicine. It operates primarily in the Boston area, its products are intended for a global market. Genosco is headquartered in Billerica, Massachusetts, the US.
For a complete picture of Cevidoplenib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
